Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study
NCT ID: NCT02155439
Last Updated: 2018-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2014-05-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
NCT04844840
Imiquimod for Preventing Keloid Recurrence
NCT03760250
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
NCT05128383
A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors
NCT03627741
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
NCT06373458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Triamcinolone
kortikosteroid
5-fluorouracil
antimitotic drug
5-fluorouracil
antimitotic drug
Triamcinolone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5-fluorouracil
antimitotic drug
Triamcinolone
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kristiina Hietanen
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampere university hospital
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-004512-22
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
140260M
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.